dc.date.accessioned2021-06-08T15:46:14Z
dc.date.available2021-06-08T15:46:14Z
dc.date.created2021-06-08T15:46:14Z
dc.date.issued2021
dc.identifierhttps://hdl.handle.net/20.500.12866/9505
dc.identifierhttps://doi.org/10.1186/s13063-021-05189-6
dc.description.abstractObjectives: The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease in all-cause in-hospital mortality among hospitalized patients with COVID-19 at 30 days in comparison with standard treatment alone. The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay.The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay
dc.languageeng
dc.publisherBioMed Central
dc.relationTrials
dc.relation1745-6215
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCOVID-19
dc.subjectRandomized controlled trial
dc.subjectMortality
dc.subjectProtocol
dc.subjectAdverse reactions
dc.subjectConvalescent plasma
dc.subjectSafety
dc.titleRandomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución